2 transcripts
RVMD
Earnings call transcript
NASDAQ
2024 Q1
8 May 24
of the regulatory packages, supporting engagement with the FDA to determine a go-forward dose and to obtain feedback on pivotal trial designs prior
RVMD
Earnings call transcript
NASDAQ
2023 Q4
26 Feb 24
these patients as we develop a more mature data set to determine progression-free survival or PFS. We've begun preparing our regulatory packages for dose
- Prev
- 1
- Next